当前位置: X-MOL 学术Nat. Cancer › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
MTSS1 suppresses mammary tumor-initiating cells by enhancing RBCK1-mediated p65 ubiquitination
Nature Cancer ( IF 23.5 ) Pub Date : 2020-01-20 , DOI: 10.1038/s43018-019-0021-y
Min Cong 1 , Yuan Wang 1 , Yang Yang 2 , Cheng Lian 1 , Xueqian Zhuang 1 , Xiaoxun Li 1 , Peiyuan Zhang 1 , Yingjie Liu 1 , Jun Tang 3 , Qifeng Yang 4 , Xue Zhang 1 , Hua Xiong 5 , Ronggui Hu 2 , Guohong Hu 1
Affiliation  

Tumor-initiating cells (TICs) are considered the culprits of cancer development and progression. Dysregulation of metastasis suppressor protein 1 (MTSS1) has been widely observed in tumor metastasis, but its functional contribution and mechanism in cancer is poorly understood. Here we report a role of MTSS1 in suppressing TICs in breast cancer. Mtss1 knockout (KO) enhances the mammary epithelial TIC subpopulation in both luminal and basal-like breast cancer mouse models. MTSS1 also suppresses tumorsphere formation in breast cancer cells. Mechanistically, MTSS1 interacts with the E3 ligase RanBP2-type and C3HC4-type zinc finger containing 1 (RBCK1) to facilitate RBCK1-mediated p65 ubiquitination and degradation, thus suppressing the NF-κB signaling pathway and tumorigenesis. In addition, actin beta-like 2 (ACTBL2) competes with RBCK1 for MTSS1 binding, leading to p65 stabilization. Importantly, MTSS1 silencing promotes patient-derived organoid formation and xenograft growth. MTSS1 downregulation in clinical tumors is also linked to worse prognosis. Overall our data reveal a new paradigm of NF-κB regulation and may have important implications in therapeutics targeting TICs.



中文翻译:

MTSS1 通过增强 RBCK1 介导的 p65 泛素化抑制乳腺肿瘤起始细胞

肿瘤起始细胞 (TIC) 被认为是癌症发展和进展的罪魁祸首。转移抑制蛋白 1 (MTSS1) 的失调已在肿瘤转移中广泛观察到,但其在癌症中的功能贡献和机制却知之甚少。在这里,我们报告了 MTSS1 在抑制乳腺癌中 TIC 中的作用。Mtss1敲除 (KO) 增强了管腔和基底样乳腺癌小鼠模型中的乳腺上皮 TIC 亚群。MTSS1 还抑制乳腺癌细胞中肿瘤球的形成。机制上,MTSS1 与 E3 连接酶 RanBP2 型和 C3HC4 型含 1 (RBCK1) 的锌指相互作用,促进 RBCK1 介导的 p65 泛素化和降解,从而抑制 NF-κB 信号通路和肿瘤发生。此外,肌动蛋白 β 样 2 (ACTBL2) 与 RBCK1 竞争 MTSS1 结合,导致 p65 稳定。重要的是,MTSS1沉默促进患者衍生的类器官形成和异种移植物生长。临床肿瘤中的 MTSS1 下调也与较差的预后有关。总体而言,我们的数据揭示了一种新的 NF-κB 调节范式,并且可能对针对 TIC 的治疗具有重要意义。

更新日期:2020-01-20
down
wechat
bug